Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

A Study to Evaluate the Efficacy and Safety of Ferric Citrate Tablet for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

To evaluate the efficacy and safety of ferric citrate tablet in the control of serum phosphorus levels in patients with chronic kidney disease undergoing hemodialysis.

Study Overview

• Status: Completed
• Conditions: End Stage Renal Disease; ESRD; Hyperphosphatemia
• Intervention / Treatment: Drug: Ferric citrate tablet; Drug: Sevelamer carbonate tablet

Detailed Description

This is a multicenter, randomized, open-label, parallel, phase III study. This study is consisting of a Screening/Washout period (14 days) and a Treatment/Observation period (12 weeks). The subjects with regular hemodialysis should stop using the phosphorus binder before the Washout period. During the Treatment period, the subjects will be randomly assigned to the ferric citrate tablets group (study group) or sevelamer carbonate tablet group (control group) in the ratio of 1:1.

• Study Type: Interventional
• Enrollment (Actual): 239
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Baotou, China
    • The First Affiliated Hospital of Baotou Medical College
  • Beijing, China
    • Beijing Tongren Hospital
  • Beijing, China
    • Peking Union Medical College Hospital
  • Changsha, China
    • Xiangya Hospital Central South University
  • Changsha, China
    • The second Xiangya hospital of central south university
  • Dalian, China
    • The Second Hospital of Dalian Medical University
  • Hohhot, China
    • The Affiliated Hospital of Inner Mongolia Medical University
  • Huai'an, China
    • The second people's hospital of Huaian
  • Jinan, China
    • Jinan Central Hospital
  • Jinan, China
    • Shandong province qianfoshan hospital
  • Nanjing, China
    • Zhongnan Hospital Southeast University
  • Nanning, China
    • The People's Hospital of Guangxi Zhuang Autonomous Region
  • Shenzhen, China
    • ShenZhen People's Hospital
  • Shijiazhuang, China
    • The Third Hospital of Hebei Medical University
  • Tianjin, China
    • General Hospital of Tianjin Medical University
  • Zhengzhou, China
    • First Affiliated Hospital of Zhengzhou University
  • Zhengzhou, China
    • Zhengzhou People's Hospital
  • Zhengzhou, China
    • Henan Provincal People's Hospital
  • Zhuzhou, China
    • ZhuZhou Central Hospital
  • Ürümqi, China
    • The first affiliated hospital of Xinjiang medical university

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Between the age of 18 and 75 years (including the boundary value) and no gender limitation;
2. Patients who maintain the hemodialysis schedule (including hemofiltration (HF) hemodialysis (HDF) hemoperfusion (HP)) as not less than 3 times a week in the 3 months before random enrollment.
3. Patients with a serum phosphorus level between 1.97 to 3.23 mmol/L (excluding the boundary value) after washout.
4. Kt/Vurea ≥1.2 or URR ≥65%.
5. Before the screening period, CKD-MBD related drug treatment is stable for more than one month, including the use of vitamin D (active vitamin D, vitamin D analogues, etc.) or calcimimetics (cinacalcet, etc.) and the dose remains unchanged.
6. The expected survival is greater than 6 months.
7. Willing to give written informed consent.

Exclusion Criteria:

1. Patients with a serum ferritin level ≥800 ng/mL or TSAT ≥50%.
2. Patients with hemochromatosis or patients receiving treatment for iron overload, or patients with paroxysmal sleep hemoglobinuria.
3. Patients who received blood transfusions within 3 months prior to Screening, or patients with hemoglobin ≤60 g/L.
4. Patients with intact-PTH >1000 pg/mL
5. Patients complicated with any of the following gastrointestinal diseases: acute peptic ulcer, chronic ulcerative colitis, localized enteritis, intestinal obstruction, habitual constipation (number of stools once per week), and chronic diarrhea (number of stools four times per day), or patients with a history of gastrectomy or enterectomy or patients who had undergone gastrointestinal surgery within 3 months prior to Screening, or patients with dysphagia.
6. Patients with impaired liver function (hepatic dysfunction or serum total bilirubin, aspartate aminotransferase or alanine aminotransferase ≥ 2 times the upper limit of normal) or patients with cirrhosis.
7. Patients with a history of parathyroidectomy (PTx) or percutaneous anhydrous ethanol injection (PEIT) within 6 months.
8. Patients with uncontrolled diabetes or uncontrolled high blood pressure or current active infectious diseases such as active viral hepatitis.
9. Patients with a history of severe allergies may be allergic to research drugs.
10. Patients with cerebrovascular disease (cerebral infarction, cerebral hemorrhage, etc.) or cardiovascular disease (congestive heart failure of Class III or severer in NYHA classification) requiring hospitalization within 6 months prior to Screening, or patients who use antiarrhythmic drugs to control arrhythmias or who use antiepileptic drugs to control seizures.
11. Patients who plan to receive a kidney transplant during the study period.
12. Patients with a history of drug and alcohol abuse
13. Patients with active or advanced malignancy.
14. Women who are pregnant or lactating
15. Patients complicated with active bleeding or requiring anticoagulation therapy with citrate in hemodialysis
16. Patients who had participated in other clinical studies within 1 month prior to Screening.
17. Patients who are not suitable for participating in the trial according to the investigator's judgment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ferric citrate tablet; Ferric citrate arm will receive ferric citrate tablets three times a day with each meal.	Drug: Ferric citrate tablet; 250mg/tablet, manufactured by Sinomune Pharmaceutical
Active Comparator: Sevelamer carbonate tablet; Sevelamer carbonate arm will receive sevelamer carbonate tablets three times a day with each meal.	Drug: Sevelamer carbonate tablet; 800 mg/tablet, manufactured by Genzyme Ireland Limited; Other Names: Renvela

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The change in serum phosphorus levels	The change in serum phosphorus levels at the end of treatment as compared to baseline (before the first dose).	12 Weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in serum phosphorus levels	Changes in serum phosphorus levels from baseline	week 2, 4, 6, 8
Area under the curve of serum phosphorus level	Area under the curve of serum phosphorus level to visit time (AUC 0-12 weeks)	week 0, 2, 4, 6, 8, 12
The proportion of subjects whose serum phosphorus levels reached the target	The proportion of subjects whose serum phosphorus levels reached the target range at week 4, 6, 8 and 12 of treatment (the standard was defined as blood phosphorus ≤1.78mmol /L, and ≥1.13mmol /L).	week 4, 6, 8 and 12
The change in serum calcium (corrected) levels.	The change in serum calcium (corrected) levels at week 4, 8 and 12 of treatment as compared to baseline.	week 4, 8 and 12
The change in the level of intact-PTH levels.	The change in the level of intact-PTH levels at week 4, 8 and 12 of treatment as compared to baseline.	week 4, 8 and 12

Collaborators and Investigators

• Sponsor: Sinomune Pharmaceutical Co., Ltd

Study record dates

Study Major Dates

• Study Start (Actual): May 24, 2019
• Primary Completion (Actual): September 13, 2022
• Study Completion (Actual): September 13, 2022

Study Registration Dates

• First Submitted: June 30, 2020
• First Submitted That Met QC Criteria: June 30, 2020
• First Posted (Actual): July 7, 2020

Study Record Updates

• Last Update Posted (Actual): April 17, 2024
• Last Update Submitted That Met QC Criteria: April 16, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Urologic Diseases; Disease Attributes; Renal Insufficiency; Phosphorus Metabolism Disorders; Chronic Disease; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Kidney Diseases; Renal Insufficiency, Chronic; Kidney Failure, Chronic; Hyperphosphatemia; Molecular Mechanisms of Pharmacological Action; Chelating Agents; Sequestering Agents; Sevelamer
• Other Study ID Numbers: CTS-CO-1642; CTR20190978 (Other Identifier: http://www.chinadrugtrials.org.cn/)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No